|
Gene: CLCA4 |
Gene summary for CLCA4 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CLCA4 | Gene ID | 22802 |
Gene name | chloride channel accessory 4 | |
Gene Alias | CaCC | |
Cytomap | 1p22.3 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q14CN2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
22802 | CLCA4 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.07e-30 | -7.56e-01 | 0.0155 |
22802 | CLCA4 | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.27e-08 | -4.21e-01 | -0.1808 |
22802 | CLCA4 | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.01e-04 | -7.61e-01 | 0.0216 |
22802 | CLCA4 | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.16e-11 | -7.22e-01 | -0.0811 |
22802 | CLCA4 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.39e-16 | -7.03e-01 | -0.1088 |
22802 | CLCA4 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.16e-24 | -4.50e-01 | -0.1954 |
22802 | CLCA4 | HTA11_2112_2000001011 | Human | Colorectum | SER | 4.85e-19 | 8.61e-01 | -0.2196 |
22802 | CLCA4 | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.67e-05 | -5.70e-01 | -0.1207 |
22802 | CLCA4 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.88e-10 | -7.46e-01 | -0.1526 |
22802 | CLCA4 | HTA11_696_2000001011 | Human | Colorectum | AD | 7.00e-24 | -6.63e-01 | -0.1464 |
22802 | CLCA4 | HTA11_866_2000001011 | Human | Colorectum | AD | 4.18e-24 | -2.66e-01 | -0.1001 |
22802 | CLCA4 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.66e-15 | -6.71e-01 | -0.059 |
22802 | CLCA4 | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.66e-03 | -5.98e-01 | -0.1706 |
22802 | CLCA4 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.03e-02 | -6.62e-01 | -0.2061 |
22802 | CLCA4 | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.01e-04 | -7.61e-01 | -0.1462 |
22802 | CLCA4 | HTA11_546_2000001011 | Human | Colorectum | AD | 8.01e-09 | -7.44e-01 | -0.0842 |
22802 | CLCA4 | HTA11_9341_2000001011 | Human | Colorectum | SER | 1.06e-02 | -7.61e-01 | -0.00410000000000005 |
22802 | CLCA4 | HTA11_7862_2000001011 | Human | Colorectum | AD | 7.96e-07 | -7.40e-01 | -0.0179 |
22802 | CLCA4 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.28e-29 | -7.61e-01 | 0.096 |
22802 | CLCA4 | HTA11_4255_2000001011 | Human | Colorectum | SER | 1.01e-04 | -7.61e-01 | 0.0446 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0015698 | Colorectum | AD | inorganic anion transport | 52/3918 | 180/18723 | 6.83e-03 | 4.22e-02 | 52 |
GO:00156981 | Colorectum | FAP | inorganic anion transport | 38/2622 | 180/18723 | 5.73e-03 | 3.67e-02 | 38 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04972 | Colorectum | AD | Pancreatic secretion | 36/2092 | 102/8465 | 1.06e-02 | 3.98e-02 | 2.54e-02 | 36 |
hsa049721 | Colorectum | AD | Pancreatic secretion | 36/2092 | 102/8465 | 1.06e-02 | 3.98e-02 | 2.54e-02 | 36 |
hsa049722 | Colorectum | SER | Pancreatic secretion | 30/1580 | 102/8465 | 5.41e-03 | 3.28e-02 | 2.38e-02 | 30 |
hsa049723 | Colorectum | SER | Pancreatic secretion | 30/1580 | 102/8465 | 5.41e-03 | 3.28e-02 | 2.38e-02 | 30 |
hsa049724 | Colorectum | MSS | Pancreatic secretion | 33/1875 | 102/8465 | 1.09e-02 | 3.75e-02 | 2.30e-02 | 33 |
hsa049725 | Colorectum | MSS | Pancreatic secretion | 33/1875 | 102/8465 | 1.09e-02 | 3.75e-02 | 2.30e-02 | 33 |
hsa049726 | Colorectum | FAP | Pancreatic secretion | 34/1404 | 102/8465 | 2.43e-05 | 2.78e-04 | 1.69e-04 | 34 |
hsa049727 | Colorectum | FAP | Pancreatic secretion | 34/1404 | 102/8465 | 2.43e-05 | 2.78e-04 | 1.69e-04 | 34 |
hsa049728 | Colorectum | CRC | Pancreatic secretion | 32/1091 | 102/8465 | 7.86e-07 | 4.37e-05 | 2.96e-05 | 32 |
hsa049729 | Colorectum | CRC | Pancreatic secretion | 32/1091 | 102/8465 | 7.86e-07 | 4.37e-05 | 2.96e-05 | 32 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CLCA4 | SNV | Missense_Mutation | c.1357N>G | p.Thr453Ala | p.T453A | Q14CN2 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CLCA4 | SNV | Missense_Mutation | c.197N>T | p.Ala66Val | p.A66V | Q14CN2 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
CLCA4 | SNV | Missense_Mutation | novel | c.2039N>T | p.Ala680Val | p.A680V | Q14CN2 | protein_coding | tolerated(0.49) | benign(0.076) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CLCA4 | SNV | Missense_Mutation | novel | c.1766N>A | p.Ser589Tyr | p.S589Y | Q14CN2 | protein_coding | tolerated(0.82) | possibly_damaging(0.781) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CLCA4 | SNV | Missense_Mutation | rs2231587 | c.629N>T | p.Cys210Phe | p.C210F | Q14CN2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A1E1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CLCA4 | SNV | Missense_Mutation | c.2312N>G | p.Ile771Ser | p.I771S | Q14CN2 | protein_coding | tolerated(0.49) | benign(0) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CLCA4 | SNV | Missense_Mutation | rs535681883 | c.1501N>A | p.Ala501Thr | p.A501T | Q14CN2 | protein_coding | tolerated(0.46) | benign(0.009) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CLCA4 | SNV | Missense_Mutation | novel | c.1913G>A | p.Gly638Glu | p.G638E | Q14CN2 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
CLCA4 | SNV | Missense_Mutation | rs200043174 | c.2696C>T | p.Thr899Met | p.T899M | Q14CN2 | protein_coding | tolerated(0.07) | benign(0.037) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CLCA4 | SNV | Missense_Mutation | c.664G>T | p.Asp222Tyr | p.D222Y | Q14CN2 | protein_coding | deleterious(0.01) | possibly_damaging(0.82) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |